![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FRMD6 |
Gene summary for FRMD6 |
![]() |
Gene information | Species | Human | Gene symbol | FRMD6 | Gene ID | 122786 |
Gene name | FERM domain containing 6 | |
Gene Alias | C14orf31 | |
Cytomap | 14q22.1 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q96NE9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
122786 | FRMD6 | CCI_1 | Human | Cervix | CC | 6.79e-28 | 2.68e+00 | 0.528 |
122786 | FRMD6 | CCI_2 | Human | Cervix | CC | 7.53e-15 | 1.50e+00 | 0.5249 |
122786 | FRMD6 | CCI_3 | Human | Cervix | CC | 1.41e-25 | 1.55e+00 | 0.516 |
122786 | FRMD6 | Tumor | Human | Cervix | CC | 1.35e-25 | 5.65e-01 | 0.1241 |
122786 | FRMD6 | sample3 | Human | Cervix | CC | 7.61e-46 | 7.70e-01 | 0.1387 |
122786 | FRMD6 | T3 | Human | Cervix | CC | 2.29e-43 | 7.73e-01 | 0.1389 |
122786 | FRMD6 | LZE4T | Human | Esophagus | ESCC | 6.49e-17 | 6.28e-01 | 0.0811 |
122786 | FRMD6 | LZE20T | Human | Esophagus | ESCC | 6.27e-05 | 3.15e-01 | 0.0662 |
122786 | FRMD6 | LZE22T | Human | Esophagus | ESCC | 1.35e-05 | 1.34e-01 | 0.068 |
122786 | FRMD6 | LZE24T | Human | Esophagus | ESCC | 8.62e-04 | 1.15e-01 | 0.0596 |
122786 | FRMD6 | P1T-E | Human | Esophagus | ESCC | 4.93e-04 | 5.74e-02 | 0.0875 |
122786 | FRMD6 | P2T-E | Human | Esophagus | ESCC | 1.95e-21 | 5.65e-01 | 0.1177 |
122786 | FRMD6 | P4T-E | Human | Esophagus | ESCC | 2.16e-16 | 3.93e-01 | 0.1323 |
122786 | FRMD6 | P5T-E | Human | Esophagus | ESCC | 3.83e-14 | 3.91e-01 | 0.1327 |
122786 | FRMD6 | P8T-E | Human | Esophagus | ESCC | 2.14e-07 | 2.61e-01 | 0.0889 |
122786 | FRMD6 | P9T-E | Human | Esophagus | ESCC | 6.04e-14 | 3.80e-01 | 0.1131 |
122786 | FRMD6 | P10T-E | Human | Esophagus | ESCC | 2.90e-22 | 6.08e-01 | 0.116 |
122786 | FRMD6 | P11T-E | Human | Esophagus | ESCC | 2.08e-15 | 1.09e+00 | 0.1426 |
122786 | FRMD6 | P12T-E | Human | Esophagus | ESCC | 2.41e-38 | 8.68e-01 | 0.1122 |
122786 | FRMD6 | P15T-E | Human | Esophagus | ESCC | 2.94e-26 | 7.36e-01 | 0.1149 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00310329 | Cervix | CC | actomyosin structure organization | 43/2311 | 196/18723 | 1.11e-04 | 1.40e-03 | 43 |
GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
GO:003103217 | Oral cavity | OSCC | actomyosin structure organization | 93/7305 | 196/18723 | 9.63e-03 | 3.41e-02 | 93 |
GO:003103224 | Oral cavity | NEOLP | actomyosin structure organization | 44/2005 | 196/18723 | 1.42e-06 | 3.58e-05 | 44 |
GO:003103215 | Prostate | BPH | actomyosin structure organization | 63/3107 | 196/18723 | 5.78e-08 | 1.57e-06 | 63 |
GO:003103216 | Prostate | Tumor | actomyosin structure organization | 63/3246 | 196/18723 | 2.94e-07 | 6.72e-06 | 63 |
GO:003103220 | Skin | AK | actomyosin structure organization | 37/1910 | 196/18723 | 1.67e-04 | 1.94e-03 | 37 |
GO:0031032110 | Thyroid | PTC | actomyosin structure organization | 91/5968 | 196/18723 | 1.35e-05 | 1.45e-04 | 91 |
GO:003103226 | Thyroid | ATC | actomyosin structure organization | 98/6293 | 196/18723 | 1.44e-06 | 1.77e-05 | 98 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa0439016 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa0439017 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa0439025 | Oral cavity | NEOLP | Hippo signaling pathway | 35/1112 | 157/8465 | 9.91e-04 | 4.85e-03 | 3.05e-03 | 35 |
hsa0439035 | Oral cavity | NEOLP | Hippo signaling pathway | 35/1112 | 157/8465 | 9.91e-04 | 4.85e-03 | 3.05e-03 | 35 |
hsa0439010 | Prostate | BPH | Hippo signaling pathway | 52/1718 | 157/8465 | 9.93e-05 | 6.00e-04 | 3.71e-04 | 52 |
hsa0439015 | Prostate | BPH | Hippo signaling pathway | 52/1718 | 157/8465 | 9.93e-05 | 6.00e-04 | 3.71e-04 | 52 |
hsa0439024 | Prostate | Tumor | Hippo signaling pathway | 54/1791 | 157/8465 | 7.52e-05 | 5.30e-04 | 3.28e-04 | 54 |
hsa0439034 | Prostate | Tumor | Hippo signaling pathway | 54/1791 | 157/8465 | 7.52e-05 | 5.30e-04 | 3.28e-04 | 54 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FRMD6 | SNV | Missense_Mutation | c.49N>T | p.Ser17Cys | p.S17C | Q96NE9 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-A5-A0GJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
FRMD6 | SNV | Missense_Mutation | c.50N>T | p.Ser17Ile | p.S17I | Q96NE9 | protein_coding | deleterious(0.02) | benign(0.038) | TCGA-A5-A0GJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
FRMD6 | SNV | Missense_Mutation | rs760183707 | c.283N>A | p.Glu95Lys | p.E95K | Q96NE9 | protein_coding | tolerated(0.75) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FRMD6 | SNV | Missense_Mutation | c.386N>T | p.Arg129Ile | p.R129I | Q96NE9 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FRMD6 | SNV | Missense_Mutation | c.62T>C | p.Phe21Ser | p.F21S | Q96NE9 | protein_coding | deleterious(0.04) | possibly_damaging(0.869) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FRMD6 | SNV | Missense_Mutation | novel | c.47N>A | p.Arg16His | p.R16H | Q96NE9 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FRMD6 | SNV | Missense_Mutation | c.386N>T | p.Arg129Ile | p.R129I | Q96NE9 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FRMD6 | SNV | Missense_Mutation | c.44N>A | p.Arg15His | p.R15H | Q96NE9 | protein_coding | tolerated(0.54) | benign(0.067) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
FRMD6 | SNV | Missense_Mutation | c.855N>T | p.Lys285Asn | p.K285N | Q96NE9 | protein_coding | deleterious(0) | possibly_damaging(0.728) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
FRMD6 | SNV | Missense_Mutation | novel | c.1462N>A | p.Leu488Ile | p.L488I | Q96NE9 | protein_coding | tolerated(0.13) | possibly_damaging(0.883) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |